Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Totzeck, M; Aide, N; Bauersachs, J; Bucerius, J; Georgoulias, P; Herrmann, K; Hyafil, F; Kunikowska, J; Lubberink, M; Nappi, C; Rassaf, T; Saraste, A; Sciagra, R; Slart, RHJA; Verberne, H; Rischpler, C.
Nuclear medicine in the assessment and prevention of cancer therapy-related cardiotoxicity: prospects and proposal of use by the European Association of Nuclear Medicine (EANM)
EUR J NUCL MED MOL I. 2023; 50(3): 792-812. Doi: 10.1007/s00259-022-05991-7 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Bucerius Jan Alexander
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Cardiotoxicity may present as (pulmonary) hypertension, acute and chronic coronary syndromes, venous thromboembolism, cardiomyopathies/heart failure, arrhythmia, valvular heart disease, peripheral arterial disease, and myocarditis. Many of these disease entities can be diagnosed by established cardiovascular diagnostic pathways. Nuclear medicine, however, has proven promising in the diagnosis of cardiomyopathies/heart failure, and peri- and myocarditis as well as arterial inflammation. This article first outlines the spectrum of cardiotoxic cancer therapies and the potential side effects. This will be complemented by the definition of cardiotoxicity using non-nuclear cardiovascular imaging (echocardiography, CMR) and biomarkers. Available nuclear imaging techniques are then presented and specific suggestions are made for their application and potential role in the diagnosis of cardiotoxicity.
Find related publications in this database (Keywords): Nuclear medicine; Cancer therapy-related cardiotoxicity; Cardio-oncology; PET; SPECT; Chemotherapy; Radiotherapy; Immunotherapy